Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. How...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/9/592 |
| _version_ | 1797580663035002880 |
|---|---|
| author | Caitlin Lazurko Revital Linder Kate Pulman Genevieve Lennox Tomer Feigenberg Rouhi Fazelzad Taymaa May Tiffany Zigras |
| author_facet | Caitlin Lazurko Revital Linder Kate Pulman Genevieve Lennox Tomer Feigenberg Rouhi Fazelzad Taymaa May Tiffany Zigras |
| author_sort | Caitlin Lazurko |
| collection | DOAJ |
| description | Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. However, LGSOC is relatively chemo-resistant and has a poor response to traditional treatments. Alternative treatments, including biologic therapies such as bevacizumab, have shown some activity in LGSOC. Thus, the objective of this systematic review is to determine the effect and safety of bevacizumab in the treatment of LGSOC. Following PRISMA guidelines, Medline ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase all from the OvidSP platform, ClinicalTrials.gov, International Clinical Trials Registry Platform, International Standard Randomised Controlled Trial Number Registry were searched from inception to February 2022. Articles describing bevacizumab use in patients with LGSOC were included. Article screening, data extraction, and critical appraisal of included studies were completed by two independent reviewers. The effect of bevacizumab on the overall response rate, progression-free survival, overall survival, and adverse effects were summarized. The literature search identified 3064 articles, 6 of which were included in this study. A total of 153 patients were analyzed; the majority had stage IIIC cancer (56.2%). The overall median response rate reported in the studies was 47.5%. Overall, bevacizumab is a promising treatment for LGSOC, with response rates higher than traditional treatment modalities such as conventional chemotherapy, and is often overlooked as a treatment tool. A prospective clinical trial evaluating the use of bevacizumab in LGSOC is necessary to provide greater evidence and support these findings. |
| first_indexed | 2024-03-10T22:53:07Z |
| format | Article |
| id | doaj.art-48278b6557e24405916fa8efc993d06c |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T22:53:07Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-48278b6557e24405916fa8efc993d06c2023-11-19T10:10:57ZengMDPI AGCurrent Oncology1198-00521718-77292023-09-013098159817110.3390/curroncol30090592Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic ReviewCaitlin Lazurko0Revital Linder1Kate Pulman2Genevieve Lennox3Tomer Feigenberg4Rouhi Fazelzad5Taymaa May6Tiffany Zigras7Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDepartment of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa 3109601, IsraelDivision of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, CanadaDivision of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, CanadaDivision of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, CanadaDepartment of Library and Information Services, University Health Network Library and Information Services, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, CanadaDivision of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, CanadaDivision of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, CanadaSerous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. However, LGSOC is relatively chemo-resistant and has a poor response to traditional treatments. Alternative treatments, including biologic therapies such as bevacizumab, have shown some activity in LGSOC. Thus, the objective of this systematic review is to determine the effect and safety of bevacizumab in the treatment of LGSOC. Following PRISMA guidelines, Medline ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase all from the OvidSP platform, ClinicalTrials.gov, International Clinical Trials Registry Platform, International Standard Randomised Controlled Trial Number Registry were searched from inception to February 2022. Articles describing bevacizumab use in patients with LGSOC were included. Article screening, data extraction, and critical appraisal of included studies were completed by two independent reviewers. The effect of bevacizumab on the overall response rate, progression-free survival, overall survival, and adverse effects were summarized. The literature search identified 3064 articles, 6 of which were included in this study. A total of 153 patients were analyzed; the majority had stage IIIC cancer (56.2%). The overall median response rate reported in the studies was 47.5%. Overall, bevacizumab is a promising treatment for LGSOC, with response rates higher than traditional treatment modalities such as conventional chemotherapy, and is often overlooked as a treatment tool. A prospective clinical trial evaluating the use of bevacizumab in LGSOC is necessary to provide greater evidence and support these findings.https://www.mdpi.com/1718-7729/30/9/592low-grade serous ovarian cancerbevacizumaboverall response rate |
| spellingShingle | Caitlin Lazurko Revital Linder Kate Pulman Genevieve Lennox Tomer Feigenberg Rouhi Fazelzad Taymaa May Tiffany Zigras Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review Current Oncology low-grade serous ovarian cancer bevacizumab overall response rate |
| title | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review |
| title_full | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review |
| title_fullStr | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review |
| title_full_unstemmed | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review |
| title_short | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review |
| title_sort | bevacizumab treatment for low grade serous ovarian cancer a systematic review |
| topic | low-grade serous ovarian cancer bevacizumab overall response rate |
| url | https://www.mdpi.com/1718-7729/30/9/592 |
| work_keys_str_mv | AT caitlinlazurko bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT revitallinder bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT katepulman bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT genevievelennox bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT tomerfeigenberg bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT rouhifazelzad bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT taymaamay bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview AT tiffanyzigras bevacizumabtreatmentforlowgradeserousovariancancerasystematicreview |